Afuco™ Anti-Human NONO ADCC Recombinant Antibody (PAT-LM1), ADCC Enhanced (CAT#: AFC-660CL)

Figure 1 shows the strategy used for fine mapping the PAT-LMl epitope on NMT55 (A and C). B) Western blots show that the PAT-LMl epitope lies between amino acids 292-306 of NMT55.

Figure 2 shows ELISA results for binding of PAT-LMl IgM to A) alanine substituted and B) serine substituted epitope sequences.

Figure 3 shows fluorescent activated cell sorting (FACS) results

A) Negative control #1 (Chrom Pure CP antibody alone); B) Negative control #2 (buffer plus PAT-LMl -epitope 2; green or Sam-3 epitope; blue); C) PAT-LMl antibody alone; D) PAT-LMl antibody plus PAT-LMl -epitope 2 (green) or Sam-3 epitope (blue). Binding of PAT-LMl antibody to cells (C) is inhibited when PAT-LMl antibody is preincubated with PAT-LMl additional epitope 2.

Figure 4 show a series of graphs of the results of MTT reduction assays for mitochondrial dehydrogenase activity.

The LM-I monoclonal antibody inhibits cell proliferation and decreases survival, or induces apoptosis of EPLC-272H epidermoid cell carcinoma of the lung cells after A) 24 hours of incubation; and B) 48 hours of incubation.

Figure 5 shows a graph showing that the LM-I antibody induces apoptosis.

A series of graphs of the results of a cell death ELISA showing that the LM-1 monoclonal antibody induces apoptosis of LOU-NH91 cells after A) 24 hours of incubation; and B) 48 hours of incubation.

Figure 6 The results of screening for antibody LM-I binding to oligosaccharides.

Figure 7 shows body weight of LM-I injected mice, which was maintained for 8 weeks post injection.

Body weight in the no injection control and non-specific IgM injected control was reduced by almost 20%, due to poor health from liver metastasis.

Figure 8 shows data indicating that LM-I antibody can reduce tumor metastasis establishment, formation, or proliferation (growth).